Latest news for Firefinch Ltd (OTC:EEYMF) Stock

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ACLZ

AEYE

AOBC

AOLS

AVVIY

AWLCF

AXION VENTURES INC by Axion Ventures Inc.

AXNVF

BBVA

BLKCF

BRVVF

BUDZ

CANB

CARB

CARS

CBYI

CNNXF

CNTMF

CRESY

CTIB

CURN

CYBL

DGRLY

DTCWY

EDUC

ELAN

ELIO

FDBL

FDMF

FLWPF

FOCS

GARWF

GEGP

GFSZY

GGAL

GTII

HCSG

ICTY

ITRN

IWSY

Kingfisher Sponsored American Depositary Receipt

KGFHY

KNBWY

LDSYF

LIBERTY HEALTH SCI ORD by Liberty Health Sciences Inc

LHSIF

MBUU

MCFT

MGXMF

MMLP

MMSI

MNGGF

MRSN

NCNA

NDLS

NNGPF

NNGRY

NOVA

NXGWF

NEXOPTIC TECHNOLOGY CORP by NexOptic Technology Corp

NXOPF

NXTD

OCANF

OGDCF

OLVRF

OPMG

OPMZ

ORBC

PCRFY

PFFOF

PFSW

PGNX

PNXPF

POLA

PRPH

QCAAF

QRTEB

RIGH

RSAIF

SEEK

SGTPY

SHEN

SKVKY

SQBG

SRGHY

SYAAF

TEFOF

THCBF

Stocks That Hit 52-Week Lows On Tuesday

AAWW

ACOR

AGGG

AMCX

AMKAF

ARLP

ATRO

ATTO

AVLIF

BACHF

BBBY

BHKLY

BIREF

BJCHF

BMRN

BMWYY

BLUE PRISM GROUP PLC ORD by Blue Prism Group PLC

BPRMF

BRTX

CAKE

CATC

CDEV

CEQXF

CFWFF

CGNSF

CHMJF

COMM

CPCAY

CRTPF

CTPCY

CTTAY

CVET

CWYCY

CYCC

DDAIF

DLAKY

DMLRY

DNKEY

DSEEY

DSFGY

DSITF

EBIX

EONGY

ESVIF

ETRN

FORR

FUPBY

GBHL

GFSZF

GHSI

GIII

GNFT

GVHIB

HDSN

HNRG

HSNGY

HUSKF

IBKR

IDCBY

IDSA

IFRX

ILUS

INAP

INPX

JBFCF

JBFCY

Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Wednesday

Firefinch Ltd

Biotech

CDC Says Disruptions In Availability Of Becton Dickinson Bactec Blood Culture Bottles Blood Culture Bottles; Issuing Health Alert Network To Inform Critical Shortage Of Becton Dickinson Bactec Blood Culture Media Bottles; Becton Dickinson Bactec Shortage Has Potential To Disrupt Patient Care By Leading To Delays In Diagnosis, Misdiagnosis, Or Other Challenges

Enphase Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) shares are trading higher by 0.35% to $105.11 Tuesday. Traders and investors are watching for the company&#8217;s <a href="https://www.benzinga.com/quote/ENPH/earnings">second-quarter earnings report</a>, which is confirmed for Tuesday&#8217;s after-hours session. According to analyst consensus estimates, Enphase is expected to report EPS of 48 cents on revenue of $309.67 million.
Given disappointing <a href="https://www.benzinga.com/news/earnings/24/04/38391465/enphase-energy-q1-earnings-revenue-eps-come-in-below-estimates-amid-softening-us-demand">first-quarter results</a>, any improvement or further decline in U.S. and European revenue will be crucial. Investors will want to see if the European growth can offset the continued softness in the U.S. market.
Updates on U.S. demand and any signs of recovery or further softening will be critical. The company's efforts to manage channel inventory and its impact on shipments will also be closely watched.
Enphase&#8217;s ability to maintain or improve its gross margin within the projected range of 42% to 45% will be significant, particularly in the face of fluctuating demand and potential pricing pressures.
Any updates or changes to the company&#8217;s guidance for the remainder of the year will also be a focal point. Clear and positive guidance can help restore investor confidence despite the first-quarter setbacks.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39906272/top-trader-flags-key-factors-to-watch-for-the-ethereum-etf-trading-launch">Top Trader Flags Key Factors To Watch For The Ethereum ETF Trading Launch</a>
<h2 class="wp-block-heading">Is ENPH A Good Stock To Buy?</h2>
When deciding whether to buy a stock, there are some key fundamentals investors may want to consider. One of these factors is revenue growth. Buying a stock is essentially a bet that the business will continue to grow and generate profits in the future.
Enphase Energy has reported average annual revenue growth of 33.97% over the past 5 years. .
It's also important to pay attention to valuation when deciding whether to buy a stock. Enphase Energy has a forward P/E ratio of 38.91. This means investors are paying $38.91 for each dollar of expected earnings in the future. The average forward P/E ratio of Enphase Energy's peers is 30.05.
Other important metrics to look at include a company's profitability, balance sheet, performance relative to a benchmark index and valuation compared to peers. For in-depth analysis tools and important financial data, check out <a href="https://pro.benzinga.com">Benzinga Pro</a>.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ENPH has a 52-week high of $182.26 and a 52-week low of $73.49.
Photo via Shutterstock.

Equities

ENPH

What's Going On With Enphase Energy (ENPH) Stock?

CRWD

GOOG

GOOGL

MSFT

CrowdStrike Crash Was Major Factor In Google-Wiz Talks Failing; Sources Say Crash Played A Role

Shares of Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are on watch Tuesday amidst reports of significant changes in its Echo devices business strategy and <a href="https://www.benzinga.com/news/earnings/24/07/39900892/visa-likely-to-report-higher-q3-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-ear">broader company initiatives.</a>
<a href="https://www.benzinga.com/markets/equities/24/07/39898236/jeff-bezos-era-downstream-impact-losing-its-mojo-amazon-ceo-andy-jassy-is-reportedly-rethinking-">Amazon&#8217;s Echo devices, </a>featuring the Alexa voice assistant, have not met financial expectations, leading to billions in losses. According to a <a href="https://www.wsj.com/tech/amazon-alexa-devices-echo-losses-strategy-25f2581a?mod=latest_headlines">Wall Street Journal report</a>, Amazon's strategy of selling Echo devices at low prices to drive sales on its e-commerce platform has resulted in over $25 billion in losses from 2017 to 2021. Customers primarily used Echo devices for free applications, such as setting alarms and checking the weather, rather than engaging in more profitable activities.
In response, Amazon&#8217;s CEO Andy Jassy is rethinking the business model and plans to introduce a paid tier for Alexa, aiming to turn around the losses. This change comes amidst skepticism from some engineers working on the project.
Despite these losses, an Amazon spokesperson highlighted the success of other ventures within the devices division, stating, &#8220;Hundreds of millions of Amazon devices are used by customers around the world and to us, there is no greater measure of success.&#8221;
What Else: Alongside this strategy shift, Amazon is integrating conversational generative AI into Alexa. The internal project, "Banyan," aims to introduce a premium version of Alexa with a subscription model, potentially costing around $5 monthly. This move is designed to better compete with new generative AI-powered chatbots from companies like Google and OpenAI.
Additionally, Amazon&#8217;s book business has experienced a resurgence, generating $16.9 billion in gross merchandise sales in the first ten months of 2022, showcasing varied performance across different sectors of the company.
Analyst Commentary: Analysts at JMP view Amazon&#8217;s 2024 Prime Day favorably and expect the event to drive durability in e-commerce sales and potentially improve margins through increased volume and fulfillment network utilization. JMP maintained a Market Outperform rating on Amazon with a $225 price target. Moreover, Morgan Stanley&#8217;s Research Analyst Brian Nowak remains optimistic about Amazon, citing AWS growth and the potential for improved North America profits. Nowak aligns with street estimates on total revenue for third-quarter and has set a new price target of $240, indicating a 30% upside.
AMZN Price Action: Amazon shares were trading 2.35% higher at $186.84 according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro. </a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/checkout/benzinga-pro-essential-2024?utm_source=BZprocontent072324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="552" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/23133932/AMZN-1024x552.png" alt="" class="wp-image-452152" style="width:471px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/23133932/AMZN-1024x552.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/23133932/AMZN-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/23133932/AMZN-768x414.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/23133932/AMZN.png 1101w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39914148/donald-trump-to-announce-a-strategic-bitcoin-reserve-crypto-bettors-think-its-unlikely-but">Donald Trump To Announce A Strategic Bitcoin Reserve? Crypto Bettors Think It&#8217;s Unlikely But Possible</a></li>
</ul>
Image Via Shutterstock.

AMZN

Amazon Shares Are Trading Higher: What You Need To Know

Editor&#8217;s note: This story has been corrected to reflect that Tesla received approval to use a steer-by-wire system in Canada. 
Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) will release its financial results for the second quarter, after the closing <a href="https://www.benzinga.com/quote/TSLA/earnings">bell on Tuesday, July 23</a>.
Analysts expect the Austin, Texas-based company to report quarterly earnings at 62 cents per share, down from 91 cents per share in the year-ago period. Tesla is expected to post revenue of $24.77 billion, compared to $24.93 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Canada recently granted the EV maker approval to use its steer-by-wire system in the country as required for testing. The technology, which does not meet the country's specification for minimum steering angle, is only available on the company's Cybertruck and not on any of its other offerings.
Tesla shares gained 5.2% to close at $251.51 on Monday.
Benzinga readers can access the latest analyst ratings on the<a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie"> Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Mizuho analyst Vijay Rakesh maintained a Neutral rating and raised the price target from $180 to $230 on July 12. This analyst has an accuracy rate of 78%.</li>
<li>Wedbush analyst Daniel Ives reiterated an Outperform rating with a price target of $300 on July 11. This analyst has an accuracy rate of 76%.</li>
<li>Goldman Sachs analyst Mark Delaney maintained a Neutral rating and boosted the price target from $175 to $248 on July 10. This analyst has an accuracy rate of 73%.</li>
<li>Truist Securities analyst William Stein maintained a Hold rating with a price target of $162 on July 3. This analyst has an accuracy rate of 88%.</li>
<li>New Street Research analyst Pierre Ferragu maintained a Buy rating with a price target of $235 on June 25. This analyst has an accuracy rate of 78%.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39881674/top-4-tech-stocks-that-may-explode-in-july">Top 4 Tech Stocks That May Explode In July</a></li>
</ul>

Earnings

Price Target

Analyst Ratings

TSLA

Tesla Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call (CORRECTED)

- Reuters Citing Message Read Aloud On Senate Floor

Macro Economic Events

Legal

Economics

U.S. Senate Has Received Resignation Of Senator Menendez

<a href="https://www.wsj.com/livecoverage/stock-market-today-earnings-dow-sp500-nasdaq-07-23-2024/card/perlmutter-sells-entire-disney-stake-after-proxy-fight-loss-BXemLjKEolk1S1EtJKhc?page=1">https://www.wsj.com/livecoverage/stock-market-today-earnings-dow-sp500-nasdaq-07-23-2024/card/perlmutter-sells-entire-disney-stake-after-proxy-fight-loss-BXemLjKEolk1S1EtJKhc?page=1</a>
Isaac "Ike" Perlmutter, the <a href="https://www.wsj.com/articles/disney-marvel-perlmutter-laid-off-fired-16821248">former Marvel Entertainment executive</a>, who for the last decade and a half has been one of Disney's largest independent shareholders, has sold his entire stake.
Perlmutter banded with activist investor Nelson Peltz <a href="https://www.wsj.com/articles/how-nelson-peltz-and-disneys-marvel-chief-teamed-up-in-proxy-fight-fcb1602f">last year in a campaign</a> to secure two seats on Disney's board of directors, contributing nearly 26 million shares to Peltz's war chest. In April, shareholders voted overwhelmingly in favor of Disney's slate, effectively endorsing CEO Bob Iger and his management team while handing Peltz and Perlmutter <a href="https://www.wsj.com/business/media/how-disneys-bob-iger-vanquished-wall-street-agitator-nelson-peltz-7f4760cc">a bruising defeat</a>.

Asset Sales

Management

Reported Earlier, 'Perlmutter Sells Entire Disney Stake After Proxy Fight Loss' - WSJ

Embecta Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>), a manufacturer of disposable <a href="https://www.benzinga.com/general/biotech/24/07/39732571/fda-rejects-novo-nordisks-weekly-insulin-requests-information-related-to-manufacturing-process-ty">insulin pen needles</a> and syringes, is considering a potential sale following a significant drop in its share price since being spun off from health tech giant Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>).
The medical technology company, which supplies approximately 8 billion syringes and needle pens annually across more than 100 countries, has engaged advisers from Centerview Partners <a target="_blank" href="https://www.benzinga.com/quote/embc" rel="noreferrer noopener">to explore a sale</a>.
Embecta&#8217;s share price has plummeted nearly 70% since its April 2022 spin-off, leaving the Nasdaq-listed firm valued at $2.1 billion.
The decline is attributed to several factors, including the impact of GLP-1 drugs such as Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic, reducing demand for traditional insulin treatments for type 2 diabetes.
Despite this, the Financial Times notes that Devdatt Kurdikar, Embecta&#8217;s CEO, remains optimistic, suggesting that the presence of GLP-1 drugs has only delayed, not eliminated, the need for insulin.
The company&#8217;s U.S. business, which generates about half of its revenue, has been particularly affected by the shift towards GLP-1 medications.
The FT <a target="_blank" href="https://www.ft.com/content/4aa65f0f-dcdf-4849-bd87-b81b23961fc1" rel="noreferrer noopener">report</a>, citing analysts, also notes that declining profit margins and the costs associated with separating from Becton Dickinson have negatively impacted Embecta&#8217;s stock performance.
For the fiscal year ending in September, Embecta&#8217;s adjusted net income is expected to decrease by 23% to $132 million, while annual revenues are projected to hold steady around $1.1 billion.
Despite the current challenges, Kurdikar points to potential growth opportunities, including increasing diabetes rates in developing regions where insulin remains the preferred treatment and the potential approval of a new insulin patch pump by the FDA, which could enhance the company&#8217;s growth prospects.
While a sale remains a possibility, the outcome is uncertain, and Embecta could continue as a listed entity.
Price Action: EMBC stock is up 7.18% at $16.27 at last check Tuesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39909352/cancer-focused-cellectar-biosciences-stock-trades-lower-despite-meeting-goal-in-blood-cancer-stud" target="_blank" rel="noreferrer noopener">Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study</a>.</li>
</ul>
Photo: Shutterstock

Health Care

Rumors

EMBC

Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Firefinch Ltd

News

Latest news for Firefinch Ltd (OTC:EEYMF) Stock

Tuesday, August 20, 2019

Thursday, August 15, 2019

Wednesday, August 14, 2019

Tuesday, August 13, 2019